Welcome to CDC Stacks | Quantifying the Economic Value and Quality of Life Impact of Earlier Influenza Vaccination - 37045 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Quantifying the Economic Value and Quality of Life Impact of Earlier Influenza Vaccination
Filetype[PDF - 810.70 KB]


Details:
  • Pubmed ID:
    25590676
  • Pubmed Central ID:
    PMC4690729
  • Description:
    Background

    Influenza vaccination is administered throughout the influenza disease season, even as late as March. Given such timing, what is the value of vaccinating the population earlier than currently being practiced?

    Methods

    We used real data on when individuals were vaccinated in Allegheny County, Pennsylvania, and the following 2 models to determine the value of vaccinating individuals earlier (by the end of September, October, and November): Framework for Reconstructing Epidemiological Dynamics (FRED), an agent-based model (ABM), and FluEcon, our influenza economic model that translates cases from the ABM to outcomes and costs [health care and lost productivity costs and quality-adjusted life-years (QALYs)]. We varied the reproductive number (R0) from 1.2 to 1.6.

    Results

    Applying the current timing of vaccinations averted 223,761 influenza cases, $16.3 million in direct health care costs, $50.0 million in productivity losses, and 804 in QALYs, compared with no vaccination (February peak, R0 1.2). When the population does not have preexisting immunity and the influenza season peaks in February (R0 1.2–1.6), moving individuals who currently received the vaccine after September to the end of September could avert an additional 9634–17,794 influenza cases, $0.6–$1.4 million in direct costs, $2.1–$4.0 million in productivity losses, and 35–64 QALYs. Moving the vaccination of just children to September (R0 1.2–1.6) averted 11,366–1660 influenza cases, $0.6–$0.03 million in direct costs, $2.3–$0.2 million in productivity losses, and 42–8 QALYs. Moving the season peak to December increased these benefits, whereas increasing preexisting immunity reduced these benefits.

    Conclusion

    Even though many people are vaccinated well after September/October, they likely are still vaccinated early enough to provide substantial cost-savings.

  • Document Type:
  • Collection(s):
  • Funding:
    1R01HS02331701/HS/AHRQ HHS/United States
    5U54HD07072503/HD/NICHD NIH HHS/United States
    R01 HS023317/HS/AHRQ HHS/United States
    U01 IP000467/IP/NCIRD CDC HHS/United States
    U54 HD070725/HD/NICHD NIH HHS/United States
No Related Documents.
You May Also Like: